Overview
This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline/Day 0 visit, participants will initiate treatment with deucravacitinib. All participants will receive deucravacitinib 12mg once-daily for 48 weeks. The treatment period will conclude at week 48.
Eligibility
Inclusion Criteria:
\-
Age ≥ 18 years (adult patient population)
- Patients receiving invasive mechanical ventilation in the intensive care unit
- Having been intubated for at least 24 hours
- Patients for whom the clinical team has decided extubation and who meet the following weaning criteria:
- Stable respiratory parameters (FiO₂ ≤ 40%, PEEP ≤ 5 cmH₂O, SpO₂ ≥ 92%)
- Hemodynamic stability (no inotropic support or minimal/stable dose)
- Appropriate neurological status (able to follow commands)
- Stable acid-base balance
- Adequate secretion control
- Technically suitable ventilator and measurement conditions
- Written informed consent obtained from the patient or legal representative
Exclusion Criteria:
- Patients with any of the following conditions will be excluded:
and
- Individuals under 18 years of age
- Pregnant patients
- Patients who do not meet the weaning criteria
- Tracheostomized patients
- Neuromuscular diseases (e.g., Guillain-Barré syndrome, Duchenne muscular dystrophy, etc.)
- Technical inadequacy preventing correct ventilator measurements
- Significant asynchrony (e.g., auto-PEEP, double triggering, ineffective triggering, cycle asynchrony, auto-triggering)
- Patients without an extubation plan or those receiving palliative care
- RASS ≤ -2 (excessive sedation) for PSV mode measurements
- RASS ≥ +2 (agitation) for PSV-CPAP mode measurements
- Patients with delirium for PSV-CPAP mode measurements
- Patients who cannot provide consent, have no legal representative, or whose representative refuses consent
